132885-40-6

Upstream product

• 123027-47-4 1-<<2-(tert-butyldimethylsiloxy)ethoxy>methyl>-6-(phenylthio)uracil 
• 74257-00-4 1-(mesitylene-2-sulfonyl)-3-nitro-1H-1,2,4-triazole 

Downstream Products

• 125057-04-7 1-[(2-hydroxyethoxy)methyl]-6-phenylthiocytosine 
• 132885-41-7 1-<<2-<(tert-butyldimethylsilyl)oxy>ethoxy>methyl>-6-(phenylthio)cytosine 
• 132885-43-9 1-<<2-<(tert-butyldimethylsilyl)oxy>ethoxy>methyl>-4,6-(diphenylthio)pyrimidin-2-one 
• 132885-42-8 6-amino-1-<<2-<(tert-butyldimethylsilyl)oxy>ethoxy>methyl>-4-(3-nitro-1,2,4-triazol-1-yl)pyrimidin-2-one 

Relevant academic research and scientific papers

Synthesis and anti-HIV activity of 2-, 3- and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)

Several analogues of a new lead for anti-HIV-1 agents, 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT), in which the C-2, N-3, or C-4 position was modified were synthesized. These involve 2-thiothymine (11), 2-thiouracil (12), 4-thiothymine (17), 4-thiouracil (18), 5-methylcytosine (27), and cytosine (28) derivatives. Preparation of N-3-substituted derivatives (29 and 30) of HEPT was also carried out. Among these analogues, compound 11 exhibited excellent activity against HIV-1 HTLV-III(B) strain with an EC50 value of 0.98 μM, which is 7-fold more potent than that of HEPT. Removal of the 5-methyl group in compound 11 results in total loss of activity. Other compounds did not show any anti-HIV-1 activity. The 4-thio derivatives 17 and 18 were found to be rather cytotoxic. When compound 11 was evaluated for its inhibitory effects on another HIV-1 strain, HTLV-III(RE), and two HIV-2 strains, LAV-2(ROD) and LAV-2(EHO), it proved equally inhibitory to HTLV-III(RF), whereas both HIV-2 strains were insensitive to the compound.